In Cartilage Repair Histogenics Resets The Stage
This article was originally published in Start Up
Executive Summary
In July Histogenics Corp. raised $49 million in a Series A recap round that will help it complete a Phase III clinical trial in articular cartilage repair. The deal also shows that Histogenics’ novel strategy for getting through the mid-stage funding gap was a success.